Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml - dobutamine

United States - English - NLM (National Library of Medicine)

a-s medication solutions - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine hydrochloride in 5% dextrose injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hy

United States - English - NLM (National Library of Medicine)

hospira, inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine 200 mg in 100 ml - dobutamine in 5% dextrose injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine in 5% dext

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - dobutamine hydrochloride 14 mg/ml - eq. dobutamine 12,5 mg/ml - concentrate for solution for infusion - 250 mg/20 ml - dobutamine hydrochloride 14 mg/ml - dobutamine

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. in patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be use prior to institution of therapy with dobutamine hydrochloride. dobutamine hydrochloride is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine injection.

Ireland - English - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - dobutamine hydrochloride - concentrate for solution for infusion - 12.5 milligram(s)/millilitre - dobutamine

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine is contraindicated in patients with idiopath

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - dobutamine hydrochloride - solution for infusion - 5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - dobutamine hydrochloride - solution for infusion - 12.5mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - dobutamine hydrochloride 14.01 mg/ml equivalent to 12.5 mg/ml dobutamine - solution for injection - 12.5 mg/ml - active: dobutamine hydrochloride 14.01 mg/ml equivalent to 12.5 mg/ml dobutamine excipient: sodium metabisulfite water for injection